Elicio Therapeutics Reports Inducement Grants

Rhea-AI Summary

Elicio Therapeutics (Nasdaq: ELTX) announced on December 16, 2025 that on December 15, 2025 it granted an aggregate of 157,193 inducement stock options to three new employees under the 2024 Inducement Incentive Award Plan.

The option exercise price is $8.52 per share, equal to the Nasdaq closing price on December 15, 2025. Grants were approved by the Compensation Committee and issued as inducements under Nasdaq Listing Rule 5635(c)(4). The awards vest over four years: 25% on the first anniversary of each start date, then the remainder vesting ratably monthly subject to continued service.

Key Figures

Inducement stock options 157,193 options Aggregate grants to three new employees under 2024 Inducement Plan

Exercise price $8.52 per share Inducement stock options grant date price on Dec 15, 2025

Number of employees 3 employees Recipients of inducement stock option grants

Vesting schedule 4 years; 25% after 1 year Remainder vests monthly thereafter, subject to continued service

Market Reality Check

$7.96 Last Close

Volume Volume 142,958 vs 20-day average 108,607, indicating elevated trading interest ahead of this filing. normal

Technical Price $8.52 is slightly above the $8.46 200-day moving average, reflecting a marginally positive longer-term trend.

Peers on Argus 1 Down

ELTX was up 4.09% while key biotech peers were mixed: NTHI -3.23%, CCCC -2.41%, IPHA +2.17%, KYTX -11.31%, SLS -0.97%. Momentum scans only flagged KYTX to the downside, suggesting ELTX trading was more stock-specific than part of a broad sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 11	Clinical trial update	Positive	+4.0%	Phase 2 AMPLIFY-7P antigen spreading and strong T cell responses reported.
Nov 19	Executive appointment	Positive	-5.5%	New CTO appointed to lead CMC, development, manufacturing, and supply chain.
Nov 13	Earnings and update	Positive	-0.9%	Q3 2025 results with narrowed net loss and extended cash runway to Q2 2026.
Nov 07	Clinical data update	Positive	-2.2%	Robust mKRAS-specific T cell responses and ELI-004 preclinical tumor eradication data.
Nov 03	Conference presentations	Neutral	-0.4%	Announcement of upcoming SITC presentations for ELI-002 and ELI-004 data.

Pattern Detected

Recent clinically positive updates often saw muted or negative reactions, with only one of several favorable trial readouts aligning with a positive price move.

Recent Company History

Over the past months, Elicio highlighted multiple immunotherapy milestones and corporate updates. Clinical releases on Nov 7 and Dec 11, 2025 detailed strong mKRAS-specific T cell responses in the Phase 2 AMPLIFY-7P trial, with one update followed by a 3.98% gain but others seeing small declines. Q3 2025 results on Nov 13 showed narrowed net loss and cash of $20.6M. A CTO appointment on Nov 19 preceded a -5.48% move. Against this backdrop, the current inducement option grants fit into ongoing organizational build-out rather than a new clinical data catalyst.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-11-13

An effective S-3 resale registration filed on Nov 13, 2025 covers up to 103,225 shares issuable from a warrant with a $7.75 exercise price. Proceeds from any selling stockholder sales would not go to the company, though the company may receive cash only if the warrant is exercised.

Market Pulse Summary

This announcement details inducement stock option grants totaling 157,193 options to three new employees at an exercise price of $8.52, vesting over four years. These awards, made under the 2024 Inducement Incentive Award Plan and aligned with Nasdaq Listing Rule 5635(c)(4), reflect ongoing team build-out around Elicio’s cancer immunotherapy programs. Investors may contextualize this with recent clinical updates and 2025 financing activities when monitoring future filings, grant activity, and progress toward upcoming clinical milestones.

Key Terms

inducement stock options financial

"Elicio granted an aggregate of 157,193 inducement stock options to three new employees"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on December 15, 2025, Elicio granted an aggregate of 157,193 inducement stock options to three new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.

Each grant provides for the purchase of shares of Elicio common stock at a price of $8.52 per share, the closing price per share of Elicio common stock as reported by Nasdaq on December 15, 2025, the date of grant.

The grants vest over four years, with 25 percent of the shares vesting on the first anniversary of each employee’s respective start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such employee’s continued service relationship with Elicio through the applicable vesting dates.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drives approximately 25% of all solid tumors. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer (“CRC”) in Phase 1 studies. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC was presented at the ESMO Immuno-Oncology Congress 2024 and included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population. In the future, Elicio plans to expand ELI-002 to other indications including mKRAS positive lung cancer and other mKRAS positive cancers. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.

Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

FAQ

How many inducement stock options did Elicio Therapeutics (ELTX) grant on December 15, 2025?

Elicio granted an aggregate of 157,193 inducement stock options on December 15, 2025.

What was the exercise price for ELTX inducement options granted December 15, 2025?

The exercise price is $8.52 per share, the Nasdaq closing price on December 15, 2025.

Who approved the December 15, 2025 ELTX option grants and under which plan?

The Compensation Committee approved the grants under the 2024 Inducement Incentive Award Plan.

What is the vesting schedule for the ELTX inducement options granted December 15, 2025?

The options vest over four years: 25% vest on the first anniversary of each employee’s start date, then vest monthly thereafter.

Were the ELTX inducement grants issued in compliance with Nasdaq rules?

Yes, the grants were issued as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received ELTX inducement grants on December 15, 2025?

Three new employees received the inducement option grants.